"While the study did not show improvement on the primary endpoint of social withdrawal, it did demonstrate significant improvement on the Clinical Global Impression of Severity scale. Secondary analyses of the data revealed significant improvement on the Vineland-II Socialization scale, a gold-standard psycho-educational measure of social function, in higher functioning patients.
“There currently are no FDA-approved therapeutics to treat the core impairments of ASD. These data represent an important advance towards addressing this serious unmet medical need,” said Paul Wang, M.D., Vice President for Clinical and Medical Affairs, Seaside Therapeutics. “ASD is a heterogeneous disorder, in terms of its etiology and its clinical presentation. This study helps us better understand which patients with ASD respond most readily to treatment with arbaclofen.”
Seaside intends to confirm its results by initiating another controlled trial of arbaclofen in patients with ASD"
 |
| http://www.businesswire.com/news/home/20130501006067/en/Seaside-Therapeutics-Announce-Results-Phase-2b-Clinical |
No comments:
Post a Comment